The Systemic Aspergillosis drugs in development market research report provides comprehensive information on the therapeutics under development for Systemic Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systemic Aspergillosis. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systemic Aspergillosis and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Systemic Aspergillosis by seven companies/universities/institutes. The top development phase for Systemic Aspergillosis is preclinical with five drugs in that stage. The Systemic Aspergillosis pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Systemic Aspergillosis pipeline products market are: Pulmonomy, Pulmatrix and Nanomerics.

The key targets in the Systemic Aspergillosis pipeline products market include Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC, Ergosterol , and Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R).

The key mechanisms of action in the Systemic Aspergillosis pipeline product include Ergosterol Inhibitor with two drugs in Preclinical. The Systemic Aspergillosis pipeline products include four routes of administration with the top ROA being Inhalational and two key molecule types in the Systemic Aspergillosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Systemic Aspergillosis overview

Aspergillosis is an opportunistic infection that usually affects the lower respiratory tract and is caused by inhaling spores of the filamentous fungus Aspergillus, commonly present in the environment. The spores germinate and develop into hyphae, which enter blood vessels and, with invasive disease, cause hemorrhagic necrosis and infarction. Symptoms may be those of asthma, pneumonia, sinusitis, or rapidly progressing systemic illness.

For a complete picture of Systemic Aspergillosis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.